BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Mental Health Issues in Pediatric Neuromuscular Disease

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Wednesday, December 9, 2020
Sponsor Information: 

This program is supported in part by an independent medical education grant from Mitsubishi Tanabe Pharma America, Inc. and Biogen.

Faculty

Avavindhan Veerapandiyan, MD
Avavindhan Veerapandiyan, MD
Pediatric Neurologist - Arkansas Children's Hospital
Hillary Zebberman
Hillary Zebberman
Clinical Social Worker - Center for Duchenne Muscular Dystrophy, ALS Neuromuscular Clinic, Pediatric Metobolic Genetics UCLA
Pediatric Mental Health Grand Round
Activity Overview: 

Hillary Zebberman from the Pediatric Neuromuscular Clinic at UCLA and Aravindhan Veerapandiyan from Arkansas Children’s Hospital provide an overview of best practices in mental health care for pediatric patients with neuromuscular disease (NMD). The webinar includes an overview of the biological and psychosocial issues that impact the mental health and emotional needs of adolescents, as well as guidance on assessing the mental health needs of this population and incorporating these considerations into the treatment plan.